Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Endocrine 1Breast 1

Conditions

Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9lutetium Lu 177 dotatate 6cabozantinib 6Nivolumab 5Ipilimumab 4fludarabine 3X-Rays 3Phantoms, Imaging 3Etoposide 3Cyclophosphamide 3CTLA-4 Antigen 3pembrolizumab 2olaparib 2aldesleukin 2Lutetium-177 2Lutetium 2Irinotecan 2Cisplatin 2Carboplatin 2trametinib 1tivozanib 1tipifarnib 1selpercatinib 1repotrectinib 1pazopanib 1gallium Ga 68 dotatate 1gallium 68 PSMA-11 1fluorodopa F 18 1fluorocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tivozanib × Endocrine × 30 days × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡